NCT04954378

Brief Summary

Retrospectively analyzed radiomics features of pancreatic ductal adenocarcinoma to predict staging and prognosis

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2010

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
11 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2020

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

June 29, 2021

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 8, 2021

Completed
Last Updated

July 8, 2021

Status Verified

June 1, 2021

Enrollment Period

11 years

First QC Date

June 29, 2021

Last Update Submit

June 29, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • radiomics features

    1409 radiomics features can be extracted from the images.

    After sketching the ROI

Study Arms (2)

Positive lymph node metastasis

pathological diagnosis :Positive lymph node metastasis

Diagnostic Test: radiomics

Negative lymph node metastasis

pathological diagnosis :Negative lymph node metastasis

Interventions

radiomicsDIAGNOSTIC_TEST
Positive lymph node metastasis

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Pancreatic tumor patients

You may qualify if:

  • radical resection was performed, and histopathologically confirmed pancreatic ductal adenocarcinoma and lymph node status;2) CT and/or MRI enhancement examinations were performed 2 weeks before surgery;3) Patients with complete clinical data

You may not qualify if:

  • (1)Patients who received radiotherapy or chemotherapy before preoperative imaging examination;2) Poor image quality.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Radiomics

Intervention Hierarchy (Ancestors)

Diagnostic ImagingDiagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Huishu Yuan

    Peking University Third Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 29, 2021

First Posted

July 8, 2021

Study Start

January 1, 2010

Primary Completion

December 30, 2020

Study Completion

December 30, 2020

Last Updated

July 8, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will not share